NeoGenomics (NASDAQ:NEO) Shares Gap Down to $27.34
NeoGenomics, Inc. (NASDAQ:NEO) shares gapped down before the market opened on Friday . The stock had previously closed at $26.28, but opened at $27.34. NeoGenomics shares last traded at $26.25, with a volume of 44,596 shares changing hands.
Several equities analysts have recently issued reports on NEO shares. Benchmark upped their price target on NeoGenomics from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, February 28th. ValuEngine upgraded NeoGenomics from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. BidaskClub upgraded NeoGenomics from a “hold” rating to a “buy” rating in a report on Thursday, March 26th. Raymond James upped their price objective on NeoGenomics from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Finally, Stephens began coverage on NeoGenomics in a report on Tuesday, April 21st. They issued an “overweight” rating and a $33.00 price target for the company. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. NeoGenomics presently has an average rating of “Buy” and an average target price of $32.25.
The firm has a 50-day moving average of $26.80 and a 200 day moving average of $27.43. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.55 and a quick ratio of 4.32. The stock has a market capitalization of $3.26 billion, a price-to-earnings ratio of 895.97 and a beta of 0.98.
NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, April 28th. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.04). The company had revenue of $106.03 million for the quarter, compared to analyst estimates of $106.03 million. NeoGenomics had a net margin of 0.82% and a return on equity of 2.95%. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period last year, the company posted ($0.03) earnings per share. On average, equities analysts forecast that NeoGenomics, Inc. will post 0.2 earnings per share for the current year.
In related news, insider Robert J. Shovlin sold 98,093 shares of NeoGenomics stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $30.86, for a total transaction of $3,027,149.98. Following the transaction, the insider now owns 249,733 shares in the company, valued at approximately $7,706,760.38. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Steven C. Jones sold 297,300 shares of NeoGenomics stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $28.77, for a total transaction of $8,553,321.00. Following the transaction, the director now owns 195,234 shares in the company, valued at approximately $5,616,882.18. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. FineMark National Bank & Trust lifted its stake in NeoGenomics by 1.6% in the 4th quarter. FineMark National Bank & Trust now owns 29,308 shares of the medical research company’s stock worth $857,000 after purchasing an additional 450 shares in the last quarter. Global Retirement Partners LLC increased its holdings in shares of NeoGenomics by 27.1% in the 1st quarter. Global Retirement Partners LLC now owns 2,110 shares of the medical research company’s stock worth $58,000 after buying an additional 450 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of NeoGenomics by 0.7% in the 4th quarter. Thrivent Financial for Lutherans now owns 83,135 shares of the medical research company’s stock worth $2,432,000 after buying an additional 614 shares during the last quarter. Sowell Financial Services LLC increased its holdings in shares of NeoGenomics by 66.1% in the 4th quarter. Sowell Financial Services LLC now owns 1,742 shares of the medical research company’s stock worth $51,000 after buying an additional 693 shares during the last quarter. Finally, Yorktown Management & Research Co Inc increased its holdings in shares of NeoGenomics by 3.8% in the 4th quarter. Yorktown Management & Research Co Inc now owns 19,000 shares of the medical research company’s stock worth $556,000 after buying an additional 700 shares during the last quarter. Institutional investors and hedge funds own 89.13% of the company’s stock.
NeoGenomics Company Profile (NASDAQ:NEO)
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Story: FAANG Stocks
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source